DLK2

Across TCGA pan-cancer cohorts, DLK2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DLK2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher DLK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DLK2 expression acts as an unfavorable survival marker.

READ, BLCA, and SARC are the cancer types where DLK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
SARC	OS	Median	All	0.210	0.745	.014	6	view →
PRAD	DFS	Median	All	0.617	0.886	.035	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DLK2–READ (OS)

Open the READ breakdown →